Zynex Amends 10-K, Details Equity & Related Party Moves

TL;DR

**ZYXIQ's 10-K/A reveals a focus on equity adjustments and related party dealings, suggesting potential underlying financial or operational shifts that warrant close scrutiny.**

AI Summary

ZYNEX INC's 10-K/A filing for the fiscal year ended December 31, 2024, primarily amends previous disclosures related to equity and related party transactions. While specific revenue and net income figures are not detailed in the provided excerpt, the amendment highlights significant activity in treasury stock, with the company engaging in repurchases during both 2023 and 2024. The filing also details changes in additional paid-in capital and retained earnings for the periods ending December 31, 2022, 2023, and 2024. Key business changes include the ongoing management of stock incentive plans, specifically the 2017 Stock Incentive Plan, and the issuance and exercise of employee stock options and warrants across various price ranges. Risks are implicitly tied to supplier concentration, noted for cost of goods total in both 2023 and 2024, and accounts receivable management. Strategic outlook involves continued equity management and potential related party transactions, such as those involving Mr. Sandgaard in May and June 2023.

Why It Matters

This 10-K/A filing provides crucial clarity on ZYNEX INC's equity structure and related party dealings, which directly impacts investor confidence and valuation models. The detailed breakdown of treasury stock activity and stock option movements offers transparency into management's capital allocation strategy. For employees, the stock incentive plan details are vital for understanding compensation and retention. Competitively, how Zynex manages its capital and potential related party transactions can signal stability or risk compared to peers in the electromedical and electrotherapeutic apparatus sector.

Risk Assessment

Risk Level: medium — The filing indicates 'us-gaap:SupplierConcentrationRiskMember' for 'us-gaap:CostOfGoodsTotalMember' in both 2023 and 2024, suggesting a reliance on a limited number of suppliers which could disrupt operations if a supplier relationship sours. Additionally, the mention of 'us-gaap:AccountsReceivableMember' for 2024 implies potential working capital management challenges. The numerous related party transactions, such as those involving Mr. Sandgaard in 2023, introduce governance risks.

Analyst Insight

Investors should scrutinize ZYNEX INC's full financial statements to understand the impact of supplier concentration on profitability and cash flow. Further investigation into the nature and terms of related party transactions, particularly those involving Mr. Sandgaard, is recommended to assess potential conflicts of interest and their effect on shareholder value.

Key Numbers

• 2024-12-31 — Conformed Period of Report (The fiscal year-end for the amended 10-K filing.)
• 2025-07-24 — Filed As Of Date (The date the 10-K/A was officially filed with the SEC.)
• 0000846475 — Central Index Key (CIK) (Unique identifier for ZYNEX INC with the SEC.)
• 001-38804 — SEC File Number (The SEC file number for ZYNEX INC.)
• 251147870 — Film Number (The film number associated with this specific SEC filing.)
• 98 — Public Document Count (The total number of public documents included in this filing.)
• 2017 — Stock Incentive Plan Year (The year of the company's active stock incentive plan.)
• 2023 — Year of Related Party Transactions (Year when Mr. Sandgaard engaged in related party transactions.)
• 2024 — Year of Supplier Concentration Risk (Year when supplier concentration risk was noted for cost of goods.)
• 3845 — SIC Code (Standard Industrial Classification for Electromedical & Electrotherapeutic Apparatus.)

Key Players & Entities

• ZYNEX INC (company) — filer of the 10-K/A
• Mr. Sandgaard (person) — involved in related party transactions on 2023-05-10 and 2023-06-13
• Zynex Monitoring Solutions (company) — associated with escrow stock as of 2021-12-22
• Bloomberg (company) — publisher of this analysis
• SEC (regulator) — recipient of the 10-K/A filing
• 9655 MAROON CIRCLE (location) — business and mail address for ZYNEX INC
• Englewood (location) — city of ZYNEX INC's business and mail address
• Colorado (location) — state of ZYNEX INC's business and mail address
• Nevada (location) — state of incorporation for ZYNEX INC
• 870403828 (number) — EIN for ZYNEX INC

FAQ

Risk Factors

• Supplier Concentration Risk [medium — operational]: The company faces supplier concentration risk, as noted for its cost of goods in both 2023 and 2024. This indicates a reliance on a limited number of suppliers, which could lead to disruptions or increased costs if those suppliers face issues.
• Accounts Receivable Management [medium — operational]: The filing implicitly highlights the importance of managing accounts receivable. While specific figures are not detailed in the excerpt, effective management is crucial for cash flow and financial health.

Industry Context

Zynex Inc. operates in the Electromedical & Electrotherapeutic Apparatus industry (SIC Code 3845). This sector is characterized by innovation in medical devices, particularly in areas like patient monitoring and pain management. The competitive landscape includes both established medical device manufacturers and emerging technology companies, with a strong emphasis on regulatory compliance and product efficacy.

Regulatory Implications

As a medical device company, Zynex is subject to stringent regulations from bodies like the FDA. The filing's focus on equity and related party transactions, while not directly regulatory, must adhere to SEC disclosure requirements. Any operational risks, such as supplier concentration, could indirectly lead to regulatory scrutiny if they impact product availability or quality.

What Investors Should Do

1. Review the specific details of the equity and related party transactions mentioned in the amendment.
2. Assess the potential impact of supplier concentration risk on the cost of goods and supply chain stability.
3. Monitor the company's treasury stock activities and their effect on outstanding shares and earnings per share.

Key Dates

• 2024-12-31: Fiscal Year End — This is the reporting period for the amended 10-K filing, providing updated financial information for the year.
• 2025-07-24: 10-K/A Filing Date — This is the date the amended annual report was officially submitted to the SEC, indicating the completion of the reporting process for the fiscal year 2024.
• 2023-05-10: Related Party Transaction (Mr. Sandgaard) — Indicates a transaction involving a key executive or related party, which requires disclosure and scrutiny by investors.
• 2023-06-13: Related Party Transaction (Mr. Sandgaard) — Further transaction involving Mr. Sandgaard, highlighting ongoing related party activities during the fiscal year 2023.
• 2023-01-01: Treasury Stock Repurchases — The company engaged in treasury stock repurchases during this period, which can impact share count and shareholder value.
• 2024-01-01: Treasury Stock Repurchases — Continued treasury stock repurchases in 2024, suggesting an ongoing strategy for managing equity.

Glossary

10-K/A

An amended annual report filed with the SEC to correct or supplement information previously filed in a 10-K. (This filing is an amendment to Zynex's 2024 annual report, indicating updates to previously disclosed information.)

Treasury Stock

Stock that a company has repurchased from the open market. It is no longer outstanding and does not have voting rights. (The filing notes significant activity in treasury stock repurchases in 2023 and 2024, impacting the company's share structure.)

Additional Paid-In Capital

The amount of money a company receives from selling stock above its par value. (Changes in this account reflect equity transactions, such as stock option exercises or grants.)

Retained Earnings

The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. (Changes in retained earnings reflect the company's profitability and dividend policy.)

Stock Incentive Plan

A plan established by a company to grant stock options or other equity awards to employees, directors, or consultants. (The 2017 Stock Incentive Plan is active, with details on issuance and exercise of options and warrants provided.)

Related Party Transactions

Transactions between a company and its management, board members, or significant shareholders, which require careful disclosure due to potential conflicts of interest. (The filing details related party transactions involving Mr. Sandgaard in May and June 2023.)

Supplier Concentration Risk

A risk that arises when a company relies heavily on a small number of suppliers for its goods or services. (This risk is explicitly mentioned in relation to Zynex's cost of goods for 2023 and 2024.)

Warrant

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. (The filing details the issuance and exercise of warrants, which can affect future share dilution.)

Year-Over-Year Comparison

This 10-K/A filing is an amendment to the previous 10-K, focusing on equity and related party transactions. Specific year-over-year comparisons of revenue, net income, or margins are not detailed in the provided excerpt. However, the amendment highlights ongoing treasury stock repurchases in both 2023 and 2024, and notes supplier concentration risk for cost of goods in both these years, suggesting continuity in these operational and financial management areas.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on July 24, 2025 by Mr. Sandgaard regarding ZYNEX INC (ZYXIQ).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR